[Evaluation of cellular and humoral immunity and individual sensitivity of T-lymphocytes to immunocorrectors in patients with diabetic retinopathy].
Patients with diabetic retinopathy were studied for parameters characterizing cell-bound and humoral immunity. Revealed in the course of our study was T-cell immune insufficiency affecting processes of proliferation of T-lymphocytes and warranting adoption of immune correction therapy. Administration of immune correctors was individualized judging from sensitivity of T-lymphocytes to the drugs being employed (splenin, thymalin, erbisol, and thymogen).
H D
HD
Zhaboiedov
N H
NH
Bychkova
R L
RL
Skrypnik
M V
MV
Sydorova
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic